Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33990361.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1376.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose.<i>See related articles by Van Tine et al., p. 3854 and Jones et al., p. 3861</i>.
Medical subject headings
- Dexrazoxane
- Razoxane
- Sarcoma